The interference between oxaliplatin & anti-EGFR therapies: a different hypothesis to explain the 'unexplainable'

Michele Basso, Vincenzo Dadduzio, Sabrina Rossi, Ettore D'Argento, Antonia Strippoli, Mariantonietta Di Salvatore, Armando Orlandi, Valeria Zurlo, Vincenzo Di Noia, Carlo Barone

Research output: Contribution to journalArticlepeer-review

Abstract

This paper has been written because we have a differing idea concerning the suspected negative interference between oxaliplatin and anti-EGFR therapies in cancer patients. Several multicenter, randomized, controlled clinical trials investigated whether the efficacy of oxaliplatin-based chemotherapy is improved by the addition of anti-EGFR therapies in patients affected by KRAS wild-type advanced colorectal cancer. Results of these trials have produced puzzling findings, with some studies demonstrating improved survival and other studies showing no differences in overall survival between experimental and control arms. Moreover, a detrimental effect has been demonstrated in some settings. Nevertheless, the extent of this interaction remains uncertain. Some physicians proposed personal interpretations. This paper describes our hypothesis.
Original languageEnglish
Pages (from-to)319-327
Number of pages9
JournalPersonalized Medicine
Volume15
Issue number4
DOIs
Publication statusPublished - Jul 1 2018

Fingerprint Dive into the research topics of 'The interference between oxaliplatin & anti-EGFR therapies: a different hypothesis to explain the 'unexplainable''. Together they form a unique fingerprint.

Cite this